

3) 研究成果の刊行に関する一覧表

a. 論文.....94 頁

- (1) Wada K, Yoshikawa T, Lee J. J., Mitsuda T, Kidouchi K, Kurosu H, Morisawa Y, Aminaka M, Okubo T, Kimura S, Moriya K; Sharp injuries in Japanese operating theaters of HIV/AIDS referral hospitals 2009-2011. *Industrial Health* 54: 224-229, 2016
- (2) 木村哲；全国保健所等における HIV 抗体検査件数と新規 HIV 感染者報告数の関連. 日本エイズ学会誌 18(1): 79-85, 2016
- (3) 木村哲；HIV 感染症の最近の動向－世界と日本の疫学状況、抗 HIV 療法(ART)の進歩等－. 感染制御 11(3): 223-229, 2016
- (4) 木村哲；HIV 感染症について. 感染と消毒 23(2): 86-92, 2016
- (5) 木村哲(監訳); 成人および青少年 HIV-1 感染者における抗レトロウイルス薬の使用に関するガイドライン 2016 年 7 月 14 日版. テクノミック, 東京, 2016
- (6) Natsuda K, et al.; APRI and FIB4 as effective markers for monitoring esophageal varices in HIV/HCV co-infected patients due to contaminated blood products for hemophilia. *Hepatol Res*. 2017 Jan 28 [Epub ahead of print]
- (7) Imanaka K, Ohkawa K, Tatsumi T, Katayama K, Inoue A, Imai Y, Oshita M, Iio S, Mita E, Fukui H, Yamada A, Hijioka T, Inada M, Doi Y, Suzuki K, Kaneko A, Marubashi S, Fukui YI, Sakamori R, Yakushijin T, Hiramatsu N, Hayashi N, Takehara T, Forum OL; Impact of branched-chain amino acid supplementation on the survival in patients with advanced hepatocellular carcinoma treated with sorafenib; a multicenter retrospective cohort study. *Hepatol Res* 46(10): 1002-10, 2016
- (8) Okanoue T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, Minami M, Imai Y, Yoshihara H, Mita E, Morikawa T, Nishiguchi S, Kawakami Y, Nomura H, Sakisaka S, Kurosaki M, Yatsuhashi H, Oketani M, Kohno H, Masumoto A, Ikeda K, Kumada H; Long-term follow-up of peginterferon- α -2a treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B patients in phase II and III studies. *Hepatol Res* 46(10): 992-1001, 2016
- (9) Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T; Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. *J Med Virol* 88(10): 1776-84, 2016
- (10) Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M; Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. *Sci Rep* 6: 24767, 2016
- (11) Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F; Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. *J Med Virol* 89: 99-105, 2017
- (12) Okushin K, Tsutsumi T, Enooku K, Fujinaga H, Kado A, Shibahara J, Fukayama M, Moriya K, Yotsuyanagi H, Koike K; The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. *J Gastroenterol* 51: 808-18, 2016
- (13) Ogishi M, Yotsuyanagi H, Moriya K, Koike K; Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia. *Sci Rep* 6: 29532. doi: 10.1038/srep29532, 2016
- (14) Ikeda H, Okuse C, Watanabe T, Matsumoto N, Matsunaga K, Shigefuku R, Hattori N, Hiraishi T, Fukuda Y, Noguchi Y, Ishii T, Shima J, Nakahara K, Yamamoto H, Yasuda H, Yotsuyanagi H, Koike K, Itoh F, Suzuki M; Can the Abbott Real Time hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy? *Turk J Gastroenterol* 27:

165-72, 2016

- (15) Asahina Y, Izumi N, Hiromitsu K, Kurosaki M, Koike K, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Hayashi N, Hiramatsu N, Yotsuyanagi H; JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. *Hepatol Res* 46: 129-65, 2016
- (16) Matsumoto C, Akiyama T, Maruta T, Higuchi S, Nakane H, Ohta J, Kanba S; ICD-11 Beta Draft Survey in Japan. *Psychiatry Clin Neurosci* 70: 422-423, 2016
- (17) 森藤香奈子, 大石和代, 花田裕子, 山本直子, 折田真紀子, 徳永瑛子, 岩永竜一郎, 吉田浩二, 井口茂, 浦田秀子, 大津留晶, 矢部博興, 松坂誠應, 田中悟郎, 中根秀之; 福島県川内村における子育て世代の抱える多重ストレスに関する質的研究. 長崎医学会雑誌 91(特集号別冊): 230-233, 2016
- (18) 徳永瑛子, 岩永竜一郎, 大石和代, 花田裕子, 森藤香奈子, 山本直子, 折田真紀子, 吉田浩二, 井口茂, 浦田秀子, 前田正治, 大津留晶, 矢部博興, 松坂誠應, 田中悟郎, 中根秀之; 東日本大震災の子どもたちへの影響～子どもの強さと困難さ尺度（SDQ）を用いて～. 長崎医学会雑誌 91(特集号別冊): 227-229, 2016
- (19) Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S; Japanese HIV-MDR Study Group; High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum. *Japanese Journal of Infectious Diseases* (in press)
- (20) Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaka T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M; Induction of IFN- λ 3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. *Gut* (in press)
- (21) Kobayashi T, Watanabe K, Yano H, Murata Y, Igari T, Nakada-Tsukui K, Yagita K, Nozaki T, Kaku M, Tsukada K, Gatanaga H, Kikuchi Y, Oka S; Underestimated amoebic appendicitis among HIV-1-infected individuals in japan. *Journal of Clinical Microbiology* (in press)
- (22) Lin Z, Kuroki K, Kuse N, Sun X, Akahoshi T, Qi Y, Chikata T, Naruto T, Koyanagi M, Murakoshi H, Gatanaga H, Oka S, Carrington M, Maenaka K, Takiguchi M; HIV-1 control by NK cells via reduced interaction between KIR2DL2 and HLA-C*12:02/C*14:03. *Cell Reports* (in press)
- (23) Murakoshi H, Koyanagi M, Chikata T, Rahman MA, Kuse N, Sakai K, Gatanaga H, Oka S, Takiguchi M; Accumulation of Pol mutations selected by HLA-B*52:01-C*12:02 protective haplotype-restricted CTLs causes low plasma viral load due to low viral fitness of mutant viruses. *Journal of Virology* (in press)
- (24) Kamori D, Hasan Z, Ohashi J, Kawana-Tachikawa A, Gatanaga H, Oka S, Ueno T; Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIV-1 chronic infection. *Journal of Medical Virology* 89: 123-129, 2017
- (25) Boonchawalit S, Harada S, Shirai N, Gatanaga H, Oka S, Matsushita S, Yoshimura K; Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization. *Japanese Journal of Infectious Diseases* 69: 236-243, 2016
- (26) Hattori J, Shiino T, Gatanaga H, Mori H, Minami R, Uchida K, Sadamasu K, Kondo M, Sugiura W, Japanese Drug Resistance HIV-1 Surveillance Network; Characteristics of transmitted drug-resistant HIV-1 in recently infected treatment-naïve patients in Japan. *Journal of Acquired Immunodeficiency Syndrome* 71: 367-373, 2016
- (27) Hosaka M, Fujisaki S, Masakane A, Hattori J, Shiino T, Gatanaga H, Shigemi U, Okazaki R, Hachiya A, Matsuda M, Ibe S, Iwatani Y, Yokomaku Y, Sugiura W, Japanese Drug Resistance HIV-1 Surveillance Network; HIV-1 CRF01_AE and subtype B transmission networks crossover: a new AE/B recombinant identified in Japan. *AIDS Research and Human Retroviruses* 32: 412-419, 2016
- (28) Ondondo B, Murakoshi H, Clutton G, Abdul-Jawad S, Wee EG, Gatanaga H, Oka S, McMichael AJ, Takiguchi M, Korber B, Hanke T; Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. *Molecular Therapy* 24: 832-842, 2016

- (29) Kinai E, Kato S, Hosokawa S, Sadatsuki M, Gatanaga H, Kikuchi Y, Lam NV, Ha DQ, Kinh NV, Liem NT, Oka S; High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. Journal of Acquired Immune Deficiency Syndrome 72: 246-253, 2016
- (30) Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H; Urinary β -2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS 30 : 1563-1571, 2016
- (31) Kobayashi T, Nishijima T, Teruya K, Aoki T, Kikuchi Y, Oka S, Gatanaga H; High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era. PLoS One 11: e0151682, 2016
- (32) Tsuboi M, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, Gatanaga H; Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era. Sexually Transmitted Infections 92: 605-610, 2016
- (33) Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H; High peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. Journal of Acquired Immune Deficiency Syndrome 72: 11-14, 2016
- (34) Sun X, Shi Y, Akahoshi T, Fujiwara M, Gatanaga H, Schonbach C, Kuse N, Appay V, Gao GF, Oka S, Takiguchi M; Effects of a single escape mutation on T cell and HIV-1 co-adaptation. Cell Reports 15: 2279-2291, 2016
- (35) Yanagawa Y, Nagata N, Watanabe K, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Akiyama J, Uemura N, Oka S; Increases in Entamoeba histolytica antibody-positive rates in human immunodeficiency virus-infected and noninfected patients in Japan: a 10-year hospital-based study of 3,514 patients. American Journal of Tropical Medicine and Hygiene 95: 604-609, 2016
- (36) Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, Gatanaga H; Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Journal of Antimicrobial Chemotherapy 71: 2760-2766, 2016
- (37) Tsuboi M, Nishijima T, Teruya K, Kikuchi Y, Gatanaga H, Oka S; Cerebral syphilitic gumma within 5 months of syphilis in HIV-infected patient. Emerging Infectious Diseases 22: 1846-1848, 2016
- (38) Nishijima T, Teruya K, Shibata S, Yanagawa Y, Kobayashi T, Mizushima D, Aoki T, Kinai E, Yazaki H, Tsukada K, Genka I, Kikuchi Y, Oka S, Gatanaga H; Incidence and risk factors for incident syphilis among HIV-1-infected men who have sex with men in a large urban HIV clinic in Tokyo 2008-2015. PLoS One 11: e0168642, 2016

b. 研究成果刊行物

なし